No conflicts of interest were declared.
CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
Version of Record online: 20 NOV 2012
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 229, Issue 3, pages 355–378, February 2013
How to Cite
Grosse-Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D. and Kunz-Schughart, L. A. (2013), CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J. Pathol., 229: 355–378. doi: 10.1002/path.4086
- Issue online: 25 JAN 2013
- Version of Record online: 20 NOV 2012
- Accepted manuscript online: 16 AUG 2012 04:57AM EST
- Manuscript Accepted: 4 AUG 2012
- Manuscript Revised: 30 JUL 2012
- Manuscript Received: 29 JUN 2012
|path4086-sup-0001-TableS1.docx||Word 2007 document||70K||Table S1. CD133 as a CSC marker in solid tumours – animal models and major findings.|
|path4086-sup-0002-TableS2.docx||Word 2007 document||40K||Table S2. Putative prognostic or predictive value of CD133 positivity in colorectal cancer patients.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.